

**This Page Is Inserted by IFW Operations
and is not a part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- **BLACK BORDERS**
- **TEXT CUT OFF AT TOP, BOTTOM OR SIDES**
- **FADED TEXT**
- **ILLEGIBLE TEXT**
- **SKEWED/SLANTED IMAGES**
- **COLORED PHOTOS**
- **BLACK OR VERY BLACK AND WHITE DARK PHOTOS**
- **GRAY SCALE DOCUMENTS**

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 9/12	A1	(11) International Publication Number: WO 98/05302 (43) International Publication Date: 12 February 1998 (12.02.98)
(21) International Application Number: PCT/GB97/01502 (22) International Filing Date: 3 June 1997 (03.06.97) (30) Priority Data: 9616237.5 1 August 1996 (01.08.96) GB (71) Applicant (for all designated States except US): NORTON HEALTHCARE LIMITED [GB/GB]; Gemini House, Flex Meadow, Harlow, Essex CM29 5TJ (GB). (72) Inventor; and (75) Inventor/Applicant (for US only): MILLER, Fiona [GB/GB]; Norton Healthcare Limited, Gemini House, Flex Meadow, Harlow, Essex CM29 5TJ (GB). (74) Agent: PAWLYN, Anthony, Neil; Urquhart-Dykes & Lord, Tower House, Merriion Way, Leeds LS2 8PA (GB).		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GI, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i>
(54) Title: AEROSOL FORMULATIONS (57) Abstract The replacement of chlorofluorohydrocarbon propellants in medical aerosols is of the utmost importance to the pharmaceutical industry. A number of formulations have been investigated. The present invention provides a medical aerosol formulation comprising a particular medicament, a fluorocarbon propellant and 6 to 25 % w/w of the total formulation of a polar co-solvent, such formulation being substantially free of surfactant. Cannisters suitable for delivering such a pharmaceutical formulation are also provided.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NI	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

-1-

AEROSOL FORMULATIONS

This invention relates to pharmaceutical formulations for inhalation aerosols. The Montreal Protocol on ozone depleting gases has made the reformulation of existing pharmaceutical aerosols for inhalation treatment containing chlorofluorohydrocarbon propellants, a matter of urgency for the pharmaceutical industry.

A number of hydrofluorocarbons (HFCs) have been the subject to toxicological testing and two in particular P134a (1,1,1,2-tetrafluoroethane) and P227 (1,1,1,2,3,3,3-heptafluoropropane) have been identified as safe for use in pharmaceutical aerosols.

A number of patent applications have been submitted in this field, the first being EP 372777, which discloses the use of four component mixtures, comprising a medicament, a surfactant, P134a and a co-solvent of higher polarity than the P134a, in the form of a solution or a suspension.

As inhalation aerosols are meant for administration to the lung, it has long been accepted that such formulations should contain as few ingredients as possible, to avoid putting unnecessary materials into the lung.

Historically, despite EP 372777, solution aerosols contained only medicament, propellant or propellant mixtures and, if necessary, co-solvent, usually ethanol, eg US 2868691. The use of a surfactant was normally unnecessary for solution aerosols. However, historically medicinal suspension aerosols have contained a surfactant eg US 3014844, as it was considered that the use of a surfactant was necessary to prevent agglomeration of particles, to prevent adhesion to the sides of the canister, and to aid valve lubrication and prevent valve sticking.

However it was disclosed in EP 616525 that it is possible to prepare medicament suspensions in a hydrofluorocarbon without the need for a surfactant, if a polar co-solvent was added. The normal co-solvent ethanol, has well established

-2-

physiological actions and being a pure absorbable liquid eliminates any possibility of residues remaining in the lung. Irritation or possible toxicity from the surfactant, many of which are mixtures of similar compounds, are avoided.

EP 616525 specifically limits the polar co-solvent level to 0.01 to 5% w/w and in particular states (page 3, line 55) that the preferred level is about 0.1% w/w.

According to a first aspect of the present invention there is provided a medicinal aerosol formulation comprising a particulate medicament, a fluorocarbon propellant and 6% to 25% w/w of the total formulation of a polar co-solvent, such formulation being substantially free of surfactant.

According to a second aspect of the present invention there is provided a medicinal aerosol formulation, comprising one or more particulate medicaments, one or more fluorocarbon or hydrocarbon or aliphatic gas propellants and 6% to 25% w/w of a polar co-solvent.

According to a third aspect of the present invention there is provided a canister suitable for delivering a pharmaceutical aerosol formulation, which comprises a container capable of withstanding the vapour pressure of the propellant used, which container is closed with a metering valve and contains a pharmaceutical aerosol formulation which comprises particulate medicament, a propellant consisting all or part of fluorocarbon and 6% to 25% of a polar co-solvent, which is substantially free of surfactant.

It has now been surprisingly found that higher levels of alcohol have beneficial results. Levels of 6% or more of ethanol produce satisfactory suspensions, which do not agglomerate on standing, and on reshaking produce finely dispersed medicament. It is believed that the higher levels of alcohol reduce the degree of deposition on the inside of the can. This is a very desirable feature. In addition, the use of these larger percentages of ethanol enables a much cheaper production process.

Medicinal aerosols can be filled either with one dose of liquid containing all of the ingredients mixed together or by

-3-

a two dose process where the first dose contains the medicament and all other ingredients, including co-solvents, surfactants, if any, ancillary compounds eg flavours, if any, and some times some of the propellant followed by a second dose of pure propellant. This two dose fill has major cost advantages in that the volume of mix for a fixed number of cans is significantly smaller enabling the use of smaller mixing vessels. In particular, with the use of the new HFC propellants, which have lower boiling points than the old CFC propellants, the use of a one dose fill may involve the use of cooled pressurised vessels to prevent evaporation of the propellant gas during mixing and filling. With the new formulations with added extra co-solvent a first mix of just medicament suspended in the co-solvent can be used, followed by a second dose of pure propellant. This means that the propellant can be dosed directly from a holding tank into the can without any need to mix and store with the other ingredients. For example a mix weight of 1g of medicament and co-solvent can be followed by 7.5g of propellant. In this way the volume to be mixed is reduced from 8.5g to 1g. All the examples in EP 616525 are of laboratory scale, where the handling problems are much easier, but all the formulations described are such that it would not be practicable to fill in two doses without mixing the propellant, as is the case with the present disclosure.

The description of the filling method given on page 5 lines 2-13 indicates that only a one dose filling method is envisaged.

In all cases of the present invention the medicament consists of a particle size suitable for inhalation into the lung and will thus be less than 100 microns, desirably less than 20 microns and preferably in the range of 1-10 microns, normally with a mean particle size 1-5 microns.

Medicaments which may be administered in aerosol formulations according to the invention include any drug useful in inhalation therapy which may be presented in a form which is substantially completely insoluble in the selected propellant.

-4-

Appropriate medicaments may thus be selected from, for example, analgesics, eg codeine, dihydromorphine, ergotamine, fentanyl or morphine; anginal preparations, eg diltiazem; antiallergics, eg cromoglycate, ketotifen or nedocromil; anti-infectives, eg cephalosporins, penicillins, streptomycin, sulphonamides, tetracyclines and pentamidine; antihistamines, eg methapyrilene; anti-inflammatories, eg beclomethasone, flunisolide, budesonide, tipredane, triamcinolone acetonide or fluticasone; antitussives, eg noscapine; bronchodilators, eg ephedrine, adrenaline, fenoterol, formoterol, isoprenaline, metaproterenol, phenylephrine, phenylpropanolamine, pirbuterol, reproterol, rimiterol, salbutamol, salmeterol, terbutaline, isoetharine, tolubuterol, orciprenaline; diuretics, eg amiloride; anticholinergics, eg ipratropium, atropine or oxitropium; hormones, eg cortisone, hydrocortisone or prednisolone; xanthines, eg aminophylline, choline theophyllinate, lysine theophyllinate or theophylline; and therapeutic proteins and peptides, eg insulin or glucagon. It will be clear to a person skilled in the art that, where appropriate, the medicaments may be used in the form of salts (eg as alkali metal or amine salts or as acid addition salts) or as esters (eg lower alkyl esters) or as solvates (eg hydrates) to optimise the activity and/or stability of the medicament and/or to minimise the solubility of the medicament in the propellant.

Preferred are those compounds which are also substantially insoluble in the co-solvent. Particularly preferred as medicament is salbutamol either as base or as a salt and especially salbutamol sulphate.

Co-solvents may be selected from polar alcohols and polyols, particularly C₂-C₆ aliphatic alcohols and polyols, such as propylene glycol, and preferably ethanol. Levels of co-solvent will be between 6% and 25% w/w of the total canister content, preferably between 10-15% w/w of canister content.

The propellant may be a hydrofluorocarbon, particularly P134a or P227. Other hydrofluorocarbons or hydrocarbons or aliphatic gases (eg Dimethylether) may be added to modify the

-5-

propellant characteristics as required.

The product is preferentially produced by weighing the active medicament and suspending it in the co-solvent. The appropriate amount of suspension is then dosed into the can, followed by a second dose of propellant or propellant mix. However, a one shot fill or any other equivalent method may be employed.

The normal medicinal product on the market has an actuator with spray orifice diameter of about 480 microns. However, with the larger percentages of ethanol envisaged in this invention, it is desirable that the co-solvent evaporates from the particles as rapidly as possible.

This is achieved by reducing the aperture to between 100-300 microns, which for the same dosage or drug, gives more rapid evaporation of the co-solvent. A particularly preferred embodiment of the invention is a combination of a level 10-15% co-solvent (normally ethanol) with a stem aperture of 150-250 microns.

The invention is further described by means of example but not in any limitative sense.

Example

Salbutamol Sulphate	0.03g
Ethanol	0.97g
Tetrafluoroethane (P134a)	7.5g

The salbutamol sulphate previously micronised to give over 90% of particles below 10 microns was weighed out and added to the ethanol. The suspension was mixed until it was smooth and uniform and then filled into the aerosol canister. The metering valve assembly was crimped (preferably vacuum crimped) on the canister and then the P134a was filled through the valve. The valve capacity is such as to deliver 100 micrograms of salbutamol, as salbutamol sulphate per actuation.

A particularly preferred use of such a canister is in a patient breath operated device rather than the normal hand

-6-

operated device. Such devices are available commercially such as those under the trade mark "Easi-Breathe".

-7-

Claims:

1. A medicinal aerosol formulation comprising a particulate medicament, a fluorocarbon propellant and 6% to 25% w/w of the total formulation of a polar co-solvent, such formulation being substantially free of surfactant.

2. A medicinal aerosol formulation, comprising one or more particulate medicaments, one or more fluorocarbon or hydrocarbon or aliphatic gas propellants and 6% to 25% w/w of a polar co-solvent.

3. A formulation as claimed in claim 1 or claim 2, wherein the medicament is an anti-allergic, a bronchodilator or an anti-inflammatory steroid.

4. A formulation as claimed in claim 3, where the medicament is ephedrine, adrenaline, fenoterol, formoterol, isoprenaline, metaproterenol, phenylephrine, phenylpropandamine, pirbuterol, reproterol, rimiterol, terbutaline, isoetharine, orciprenaline, salbutamol, salmeterol, sodium cromoglycate, fluticasone, beclomethasone or similar molecule and any physiologically acceptable salt, solvate or ester of such compound.

5. A formulation, as claimed in claims 1-3, where the medicament is a salt of salbutamol.

6. A formulation, as claimed in claims 1-3, where the medicament is a salt of formoterol (sometimes called eformoterol).

7. A formulation according to any of claims 1 to 5, wherein the propellant is 1,1,1,2-tetrafluoroethane or 1,1,1,2,3,3,3-heptafluoro-n-propane.

8. A formulation according to any of claims 1 to 5,

-8-

where the co-solvent level is 10-15%.

9. A formulation according to any of claims 1-5, wherein the polar co-solvent is ethanol.

10. A canister suitable for delivering a pharmaceutical aerosol formulation, which comprises a container capable of withstanding the vapour pressure of the propellant used, which container is closed with a metering valve and contains a pharmaceutical aerosol formulation which comprises particulate medicament, a propellant consisting all or part of fluorocarbon and 6% to 25% of a polar co-solvent, which is substantially free of surfactant.

11. A canister according to claim 9, fitted into an adaptor with an aperture of 100-300 microns.

12. A product according to claims 9 and 10 where the medicament is as per claim 4.

13. A product according to claims 9-11, where the medicament is a salt of salbutamol.

14. A product according to claims 9-11, where the medicament is a salt of formoterol.

15. A canister according to claims 9 and 10, which is actuated by a breath operated device.

16. A product according to claim 15, where the medicament is a salt of salbutamol.

17. A product according to claim 15, where the medicament is a salt of formoterol.

INTERNATIONAL SEARCH REPORT

Intern al Application No
PCT/GB 97/01502

A. CLASSIFICATION OF SUBJECT MATTER

A 61 K 9/12

According to International Patent Classification (IPC) or to both national classification and IPC ⁶

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

A 61 K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO, A, 93/11 745 (GLAXO GROUP LIMITED) 24 June 1993 (24.06.93), abstract; claims 1-15. --	1-5, 7-10
A	WO, A, 93/11 743 (GLAXO GROUP LIMITED) 24 June 1993 (24.06.93), abstract; claims 1-21. --	1-5, 7-10
A	WO, A, 94/03 153 (GLAXO GROUP LIMITED) 17 February 1994 (17.02.94), abstract; claims 1-12. --	1-5, 7-10
A	WO, A, 94/13 262 (JAGER et al.) 23 June 1994 (23.06.94), abstract; claims 1-38,	1-5, 7-9

☒ Further documents are listed in the continuation of box C.☐ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

A document member of the same patent family

Date of the actual completion of the international search
03 September 1997

Date of mailing of the international search report

26.09.97

Name and mailing address of the ISA

European Patent Office, P.O. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+ 31-70) 340-3016

Authorized officer

SCHNASS e.h.

INTERNATIONAL SEARCH REPORT

-2-

International Application No
PCT/GB 97/01502

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
	<p>especially claim 4.</p> <p>----</p>	

ANNEXE

au rapport de recherche inter-
national relatif à la demande de brevet
international n°

PCT/GB 97/01302 SAE 162218

La présente annexe indique les membres de la famille de brevets relatifs aux documents de brevets cités dans le rapport de recherche international visée ci-dessus. Les renseignements fournis sont donnés à titre indicatif et n'engagent pas la responsabilité de l'Office.

In Recherchenbericht angeführtes Patentdokument Patent document cited in search report Document de brevet cité dans le rapport de recherche	Datum der Veröffentlichung Publication date Date de publication	Mitglied(er) der Patentfamilie Patent family member(s) Membre(s) de la famille de brevets	Datum der Veröffentlichung Publication date Date de publication
WO A1 9311745		AP A0 9200461	93-01-09
		AP A E 402	93-01-09
		AT A 128350	93-01-09
		AU A1 1083507	93-01-09
		AU A1 1083517	93-01-09
		AU A1 1083527	93-01-09
		AU A1 1083537	93-01-09
		AU A1 1083547	93-01-09
		AU A1 1083557	93-01-09
		AU A1 1083567	93-01-09
		AU A1 1083577	93-01-09
		AU A1 1083587	93-01-09
		AU A1 1083597	93-01-09
		AU A1 1083607	93-01-09
		AU A1 1083617	93-01-09
		AU A1 1083627	93-01-09
		AU A1 1083637	93-01-09
		AU A1 1083647	93-01-09
		AU A1 1083657	93-01-09
		AU A1 1083667	93-01-09
		AU A1 1083677	93-01-09
		AU A1 1083687	93-01-09
		AU A1 1083697	93-01-09
		AU A1 1083707	93-01-09
		AU A1 1083717	93-01-09
		AU A1 1083727	93-01-09
		AU A1 1083737	93-01-09
		AU A1 1083747	93-01-09
		AU A1 1083757	93-01-09
		AU A1 1083767	93-01-09
		AU A1 1083777	93-01-09
		AU A1 1083787	93-01-09
		AU A1 1083797	93-01-09
		AU A1 1083807	93-01-09
		AU A1 1083817	93-01-09
		AU A1 1083827	93-01-09
		AU A1 1083837	93-01-09
		AU A1 1083847	93-01-09
		AU A1 1083857	93-01-09
		AU A1 1083867	93-01-09
		AU A1 1083877	93-01-09
		AU A1 1083887	93-01-09
		AU A1 1083897	93-01-09
		AU A1 1083907	93-01-09
		AU A1 1083917	93-01-09
		AU A1 1083927	93-01-09
		AU A1 1083937	93-01-09
		AU A1 1083947	93-01-09
		AU A1 1083957	93-01-09
		AU A1 1083967	93-01-09
		AU A1 1083977	93-01-09
		AU A1 1083987	93-01-09
		AU A1 1083997	93-01-09
		AU A1 1084007	93-01-09
		AU A1 1084017	93-01-09
		AU A1 1084027	93-01-09
		AU A1 1084037	93-01-09
		AU A1 1084047	93-01-09
		AU A1 1084057	93-01-09
		AU A1 1084067	93-01-09
		AU A1 1084077	93-01-09
		AU A1 1084087	93-01-09
		AU A1 1084097	93-01-09
		AU A1 1084107	93-01-09
		AU A1 1084117	93-01-09
		AU A1 1084127	93-01-09
		AU A1 1084137	93-01-09
		AU A1 1084147	93-01-09
		AU A1 1084157	93-01-09
		AU A1 1084167	93-01-09
		AU A1 1084177	93-01-09
		AU A1 1084187	93-01-09
		AU A1 1084197	93-01-09
		AU A1 1084207	93-01-09
		AU A1 1084217	93-01-09
		AU A1 1084227	93-01-09
		AU A1 1084237	93-01-09
		AU A1 1084247	93-01-09
		AU A1 1084257	93-01-09
		AU A1 1084267	93-01-09
		AU A1 1084277	93-01-09
		AU A1 1084287	93-01-09
		AU A1 1084297	93-01-09
		AU A1 1084307	93-01-09
		AU A1 1084317	93-01-09
		AU A1 1084327	93-01-09
		AU A1 1084337	93-01-09
		AU A1 1084347	93-01-09
		AU A1 1084357	93-01-09
		AU A1 1084367	93-01-09
		AU A1 1084377	93-01-09
		AU A1 1084387	93-01-09
		AU A1 1084397	93-01-09
		AU A1 1084407	93-01-09
		AU A1 1084417	93-01-09
		AU A1 1084427	93-01-09
		AU A1 1084437	93-01-09
		AU A1 1084447	93-01-09
		AU A1 1084457	93-01-09
		AU A1 1084467	93-01-09
		AU A1 1084477	93-01-09
		AU A1 1084487	93-01-09
		AU A1 1084497	93-01-09
		AU A1 1084507	93-01-09
		AU A1 1084517	93-01-09
		AU A1 1084527	93-01-09
		AU A1 1084537	93-01-09
		AU A1 1084547	93-01-09
		AU A1 1084557	93-01-09
		AU A1 1084567	93-01-09
		AU A1 1084577	93-01-09
		AU A1 1084587	93-01-09
		AU A1 1084597	93-01-09
		AU A1 1084607	93-01-09
		AU A1 1084617	93-01-09
		AU A1 1084627	93-01-09
		AU A1 1084637	93-01-09
		AU A1 1084647	93-01-09
		AU A1 1084657	93-01-09
		AU A1 1084667	93-01-09
		AU A1 1084677	93-01-09
		AU A1 1084687	93-01-09
		AU A1 1084697	93-01-09
		AU A1 1084707	93-01-09
		AU A1 1084717	93-01-09
		AU A1 1084727	93-01-09
		AU A1 1084737	93-01-09
		AU A1 1084747	93-01-09
		AU A1 1084757	93-01-09
		AU A1 1084767	93-01-09
		AU A1 1084777	93-01-09
		AU A1 1084787	93-01-09
		AU A1 1084797	93-01-09
		AU A1 1084807	93-01-09
		AU A1 1084817	93-01-09
		AU A1 1084827	93-01-09
		AU A1 1084837	93-01-09
		AU A1 1084847	93-01-09
		AU A1 1084857	93-01-09
		AU A1 1084867	93-01-09
		AU A1 1084877	93-01-09
		AU A1 1084887	93-01-09
		AU A1 1084897	93-01-09
		AU A1 1084907	93-01-09
		AU A1 1084917	93-01-09
		AU A1 1084927	93-01-09
		AU A1 1084937	93-01-09
		AU A1 1084947	93-01-09
		AU A1 1084957	93-01-09
		AU A1 1084967	93-01-09
		AU A1 1084977	93-01-09
		AU A1 1084987	93-01-09
		AU A1 1084997	93-01-09
		AU A1 1085007	93-01-09
		AU A1 1085017	93-01-09
		AU A1 1085027	93-01-09
		AU A1 1085037	93-01-09
		AU A1 1085047	93-01-09
		AU A1 1085057	93-01-09
		AU A1 1085067	93-01-09
		AU A1 1085077	93-01-09
		AU A1 1085087	93-01-09
		AU A1 1085097	93-01-09
		AU A1 1085107	93-01-09
		AU A1 1085117	93-01-09
		AU A1 1085127	93-01-09
		AU A1 1085137	93-01-09
		AU A1 1085147	93-01-09
		AU A1 1085157	93-01-09
		AU A1 1085167	93-01-09
		AU A1 1085177	93-01-09
		AU A1 1085187	93-01-09
		AU A1 1085197	93-01-09
		AU A1 1085207	93-01-09
		AU A1 1085217	93-01-09
		AU A1 1085227	93-01-09
		AU A1 1085237	93-01-09
		AU A1 1085247	93-01-09
		AU A1 1085257	93-01-09
		AU A1 1085267	93-01-09
		AU A1 1085277	93-01-09
		AU A1 1085287	93-01-09
		AU A1 1085297	93-01-09
		AU A1 1085307	93-01-09
		AU A1 1085317	93-01-09
		AU A1 1085327	93-01-09
		AU A1 1085337	93-01-09
		AU A1 1085347	93-01-09
		AU A1 1085357	93-01-09
		AU A1 1085367	93-01-09
		AU A1 1085377	93-01-09
		AU A1 1085387	93-01-09
		AU A1 1085397	93-01-09
		AU A1 1085407	93-01-09
		AU A1 1085417	93-01-09
		AU A1 1085427	93-01-09
		AU A1 1085437	93-01-09
		AU A1 1085447	93-01-09
		AU A1 1085457	93-01-09
		AU A1 1085467	93-01-09
		AU A1 1085477	93-01-09
		AU A1 1085487	93-01-09
		AU A1 1085497	93-01-09
		AU A1 1085507	93-01-09
		AU A1 1085517	93-01-09
		AU A1 1085527	93-01-09
		AU A1 1085537	93-01-09
		AU A1 1085547	93-01-09
		AU A1 1085557	93-01-09
		AU A1 1085567	93-01-09
		AU A1 1085577	93-01-09
		AU A1 1085587	93-01-09
		AU A1 1085597	93-01-09
		AU A1 1085607	93-01-09
		AU A1 1085617	93-01-09
		AU A1 1085627	93-01-09
		AU A1 1085637	93-01-09
		AU A1 1085647	93-01-09
		AU A1 1085657	93-01-09
		AU A1 1085667	93-01-09
		AU A1 1085677	93-01-09
		AU A1 1085687	93-01-09
		AU A1 1085697	93-01-09
		AU A1 1085707	93-01-09
		AU A1 1085717	93-01-09
		AU A1 1085727	93-01-09
		AU A1 1085737	93-01-09
		AU A1 1085747	93-01-09
		AU A1 1085757	93-01-09
		AU A1 1085767	93-01-09
		AU A1 1085777	93-01-09
		AU A1 1085787	93-01-09
		AU A1 1085797	93-01-09
		AU A1 1085807	93-01-09
		AU A1 1085817	93-01-09
		AU A1 1085827	93-01-09
		AU A1 1085837	93-01-09
		AU A1 1085847	93-01-09
		AU A1 1085857	93-01-09
		AU A1 1085867	93-01-09
		AU A1 1085877	93-01-09
		AU A1 1085887	93-01-09
		AU A1 1085897	93-01-09
		AU A1 1085907	93-01-09
		AU A1 1085917	93-01-09
		AU A1 1085927	93-01-09
		AU A1 1085937	93-01-09
		AU A1 1085947	93-01-09
		AU A1 1085957	93-01-09
		AU A1 1085967	93-01-09
		AU A1 1085977	93-01-09
		AU A1 1085987	93-01-09
		AU A1 1085997	93-01-09
		AU A1 1086007	93-01-09
		AU A1 1086017	93-01-09
		AU A1 1086027	93-01-09
		AU A1 1086037	93-01-09
		AU A1 1086047	93-01-09
		AU A1 1086057	93-01-09
		AU A1 1086067	93-01-09
		AU A1 1086077	93-01-09
		AU A1 1086087	93-01-09
		AU A1 1086097	93-01-09
		AU A1 1086107	93-01-09
		AU A1 1086117	93-01-09
		AU A1 1086127	93-01-09
		AU A1 1086137	93-01-09
		AU A1 1086147	93-01-09
		AU A1 1086157	93-01-09
		AU A1 1086167	93-01-09
		AU A1 1086177	93-01-09
		AU A1 1086187	93-01-09
		AU A1 1086197	93-01-09
		AU A1 1086207	93-01-09
		AU A1 1086217	93-01-09
		AU A1 1086227	93-01-09
		AU A1 1086237	93-01-09
		AU A1 1086247	93-01-09
		AU A1 1086257	93-01-09
		AU A1 1086267	93-01-09
		AU A1 1086277	93-01-09
		AU A1 1086287	93-01-09
		AU A1 1086297	93-01-09
		AU A1 1086307	93-01-09
		AU A1 1086317	93-01-09
		AU A1 1086327	93-01-09
		AU A1 1086337	93-01-09
		AU A1 1086347	93-01-09
		AU A1 1086357	93-01-09
		AU A1 1086367	93-01-09
		AU A1 1086377	93-01-09
		AU A1 1086387	93-01-09
		AU A1 1086397	93-01-09
		AU A1 1086407	93-01-09
		AU A1 1086417	93-01-09
		AU A1 1086427	93-01-09
		AU A1 1086437	93-01-09
		AU A1 1086447	93-01-09
		AU A1 108645	

